Seres Therapeutics, Inc. (MCRB)

Pharmaceutical Preparations · market cap $39M · as of 2026-07-16

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-04 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Seres Therapeutics (MCRB) is a 103-employee pharmaceutical company with a market cap of ~$51M and a single clinical-stage asset, SER-109, in Phase 3 for recurrent Clostridium difficile infection. The company holds $29.8M in cash against a runway of roughly 5.5 months, creating acute near-term financing pressure. Revenue history is erratic, and the financials suggest the company is burning cash rapidly with minimal commercial income.

The catalyst path

2026-11-04 (est.)Earningsimp 5/10

Pipeline

Asset	Phase	Indication
SER-109	Phase 3	Clostridium Difficile Infection

Price & technical context

3-month

-61.5%

6-month

-68.0%

12-month

-85.5%

52-wk range

$2.93–$28.63

vs 50-day MA

-35.2%

vs 200-day MA

-64.7%

Realized vol

95.5%

Max drawdown

-89.8%

Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for MCRB (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.